Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis

A technology for Lactobacillus rhamnosus and ulcerative colitis, applied in the field of functional microorganisms, can solve the problems of few strains and poor effect, etc.

Active Publication Date: 2021-04-09
JIANGNAN UNIV
View PDF8 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the problem that currently there are few bacterial strains that can be used to alleviate the symptoms of ulcerative colitis, or the effect is not good, the present invention has screened out probiotics that can effectively relieve symptoms related to ulcerative colitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis
  • Application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis
  • Application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Tolerance of Lactobacillus rhamnosus CCFM1129 to simulated gastrointestinal fluid

[0053] The cryopreserved Lactobacillus rhamnosus CCFM1129 was inoculated on the mMRS plate, cultured anaerobically at 37° C. for 48 hours, and subcultured 2 to 3 times with the mMRS culture medium to obtain the culture medium of Lactobacillus rhamnosus CCFM1129.

[0054] Take 1 mL of the culture solution of Lactobacillus rhamnosus CCFM1129, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (containing 1% pepsin, mMRS medium at pH = 2.5), and culture it anaerobically at 37°C. Samples were taken at 0.5h, 1h, 2h, and 3h, and the mMRS agar medium was poured to culture the plate colonies, and the number of viable bacteria was determined and the survival rate was calculated.

[0055] Take 1 mL of the culture solution of Lactobacillus rhamnosus CCFM1129 and add it into 9 mL of artificial simulated intestinal fluid (mMRS medium containing 0.3% bovine bile salt, 1% trypsi...

Embodiment 2

[0061] Example 2: Lactobacillus rhamnosus CCFM1129 has no toxic side effects on C57BL / 6J mice

[0062] Resuspend Lactobacillus rhamnosus CCFM1129 in 3g / 100mL sucrose solution to make a concentration of 5.0×10 9 CFU / mL bacterial suspension. Take 6 healthy male C57BL / 6J mice with a body weight of about 14-16g. After adapting to the environment for a week, they are given the bacterial suspension of this concentration by gavage once a day (0.2mL per gavage), observed for a week, and recorded the death and body weight. .

[0063] The results of these tests are listed in Table 3. These results indicated that feeding concentrations of 5.0×10 9 CFU / mL of Lactobacillus rhamnosus CCFM1129 had no significant impact on mice, no significant change in body weight, and no death. The appearance of the mice had no obvious pathological symptoms.

[0064] Table 3 Changes in body weight and death of mice

[0065] time (days) 1 2 3 4 5 6 7 weight(g) 19.53±0.32 19.72±0...

Embodiment 3

[0067] Example 3: Effect of Lactobacillus rhamnosus CCFM1129 on disease symptoms in UC mice:

[0068] Take 30 healthy male C57BL / 6J mice weighing 14-16g, adapt to the environment for 1 week, 6 mice in each group, and randomly divide them into 5 groups: blank group, model group, drug group, Lactobacillus rhamnosus CCFM1129 intervention group (CCFM1129), Lactobacillus rhamnosus FXJWS44-L2 control group (FXJWS44-L2). The dose of intragastric bacterial suspension was 5.0×10 9 CFU / mL, resuspended in 3g / 100mL sucrose solution, 0.2mL per gavage. In the fifth week, dextran sodium sulfate (dextran sulphate sodium, DSS) with a final concentration of 2.5 g / 100 mL was added to drinking water for 7 days to induce colitis in mice. The grouping and treatment methods of experimental animals are shown in Table 4:

[0069] Table 4 Animal grouping and treatment methods

[0070]

[0071] In the fifth week, during the modeling period (DSS treatment period), the body weight of the mice was r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. The lactobacillus rhamnosus can tolerate the gastrointestinal environment of a human body, significantly reduce weight loss during the period of ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, and reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon. The transcription levels of colon close junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, antibacterial peptides Reg3g and Reg3b and mucoprotein MUC2 are up-regulated, the abundance of short-chain fatty acid producing bacteria Coprococcus and Faecalibacterium and the content of short-chain fatty acid are improved, the abundance of beneficial bacteria Lactobacillus in intestinal tracts is increased, the abundance of the conditional pathogenic bacteria Acinetobacter is reduced, and the abundance and diversity of intestinal flora are increased.

Description

technical field [0001] The application of a strain of Lactobacillus rhamnosus in preventing and alleviating ulcerative colitis belongs to the technical field of functional microorganisms. Background technique [0002] Ulcerative colitis (UC) is a kind of inflammatory bowel disease (Inflammatory bowel disease, IBD), the main clinical manifestations are chronic or subacute diarrhea, mucus pus and blood in the stool and abdominal pain. UC is a continuous inflammation of colonic mucosa and submucosa, and the disease usually starts from the rectum and spreads to the whole colon. UC has a long course of disease and is prone to recurrence, which not only affects the quality of life of patients, but also increases the risk of colorectal cancer in patients. At present, the pathogenesis of UC is still unclear. Studies have shown that it is mainly related to immune factors, intestinal flora, genetic factors and environmental factors. , self-antigens, etc. produce an unrestricted immu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A61K35/747A61P1/00A61P1/04A23L33/135A23L29/00A23C9/123A23L11/50A23C13/16A23C19/00A23L19/00C12R1/225
CPCA61K35/747A61P1/00A61P1/04A23L33/135A23L29/065A23C9/1234A23C13/16A23C19/00A23L19/00A23V2002/00A23V2400/175A23V2200/3204
Inventor 王刚郑雨星王琳琳翟齐啸陆文伟于雷雷张秋香崔树茂杨波毛丙永唐鑫赵建新张灏陈卫
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com